A novel external counterpulsation system for coronary artery disease and heart failure: pilot studies and initial

Tsuyoshi Shimizu1, Shunei Kyo, Kazuhito Imanaka

  • 1Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. tshimizu-cvs@umin.ac.jp

Insights

A novel external counterpulsation (ECP) system, Compact CP, demonstrated safety and effectiveness in pilot studies for coronary artery disease and heart failure. This innovative device shows promise for improving patient outcomes with no adverse effects observed.

Area of Science:

  • Cardiovascular Medicine
  • Biomedical Engineering

Background:

  • External counterpulsation (ECP) is a noninvasive treatment for cardiovascular conditions but has limitations.
  • Existing ECP systems can be bulky and impactful due to cuff inflation and compressor size.

Purpose of the Study:

  • To evaluate a novel ECP system, Compact CP, featuring a double-lumen cuff.
  • To assess the safety, efficacy, and comfort of the Compact CP system in healthy volunteers and patients with cardiovascular diseases.

Main Methods:

  • The Compact CP system utilizes a double-lumen cuff: a contact cuff with constant pressure and a main cuff synchronized to the cardiac cycle.
  • Four pilot studies were conducted on 39 healthy volunteers, alongside initial clinical application in three patients.

Main Results:

  • The system achieved significant diastolic augmentation and systolic unloading in pilot studies.
  • A satisfactory diastolic/systolic pressure ratio (1.00 ± 0.06) and high comfort were noted at 40 kPa driving pressure.
  • Clinical improvements were observed in patients with chronic refractory angina and heart failure, with no adverse effects.

Conclusions:

  • The novel Compact CP ECP system is safe and effective for treating coronary artery disease and heart failure.
  • The system demonstrates promising results, warranting further clinical investigation.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...